Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib — Stella
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(19 sites) United States
University of Alabama at Birmingham, Birmingham, Alabama Gabrail Cancer Center, Canton, Ohio University of Cincinnati (UC), Cincinnati, Ohio The University of Texas MD Anderson Cancer Center, Houston, Texas France
AP-HM - Hôpital de la Timone, Marseille CHU de Nice - Hopital L'Archet II, Nice Hôpital Saint Louis - AP-HP, Paris Centre Hospitalier Lyon Sud, Pierre-Bénite Germany
Marien Hospital Duesseldorf, Düsseldorf Klinik fur Innere Medizin IV - Hamatologie/Onkologie, Universitatsklinikum Hall, Halle Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola, Bologna Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan Azienda Ospedaliera di Perugia-Ospedale S. Maria della Misericordia, Perugia Poland
Pratia Onkologia Katowice, Katowice Spain
Hospital Universitari Arnau de Vilanova, Lleida Hospital Universitario Ramon y Cajal, Madrid Hospital Universitario Virgen de la Victoria, Málaga Hospital Quironsalud de Zaragoza, Zaragoza
Last updated February 2023